前列腺癌耐药性与雄激素受体剪接变异体7关系的研究进展  

Progress in the study about androgen receptor splicing variants 7 and the drug resistant of prostate cancer

作　　者：刘瑾 李文平[1] Liu Jin;Li Wenping(Department of Urology, the Third Hospital of Hebei Medical University, Shijiazhang 050051, China)

机构地区：[1]河北医科大学第三医院泌尿外科,石家庄050051

出　　处：《中华实验外科杂志》2019年第4期790-792,共3页Chinese Journal of Experimental Surgery

摘　　要：前列腺癌是老年男性常见的泌尿生殖系统恶性肿瘤。雄激素剥夺疗法通过阻断雄激素的合成,或竞争性结合雄激素受体,可明显抑制转移癌进展,但多数患者最终出现雄激素抵抗,成为转移性去势抵抗型前列腺癌(mCRPC)。近年来有关研究表明,雄激素受体剪接变异体7与mCRPC的发生发展、及其对雄激素受体信号传导抑制剂(恩杂鲁胺和阿比特龙)耐药性的产生密切相关。Prostate cancer is an urogenital malignancy which is common in older men. Androgen deprivation therapy is an usual treatment for metastatic prostate cancer significantly inhibiting the progression of advanced prostate cancer via blocking androgen synthesis, or competitive binding to androgen receptors. Nevertheless, most of the patients end up with metastatic castration-resistant prostate cancer (mCRPC) on the account of androgen resistance. It has been shown that androgen receptor splice variant 7 is strongly associated with the development of mCRPC and its drug resistance to androgen receptor signal transduction inhibitors (enzalutamide and abiraterone) in studies of recent years.

关 键 词：转移性去势抵抗型前列腺癌 雄激素受体剪接变异体7 抗雄激素治疗耐药性 

分 类 号：R737.25[医药卫生—肿瘤]